Inside the dying neurons of people with Alzheimer's disease, scientists have spotted something striking: the cell's control center—the nucleus—shrivels and collapses before the cell itself dies. This distinct pattern of decay, now formally identified and named karyoptosis, represents a previously unknown mechanism of cell death that may explain how toxic proteins trigger the devastating loss of brain cells in dementia.
Researchers at King's College London, working with the UK Dementia Research Institute, have found clear markers of karyoptosis in the brains of patients with Alzheimer's and frontotemporal dementia. The discovery, published in Nature Communications, caps a decade of investigation that began with observing this strange cell death in rarer diseases and has now revealed it as a common thread running through dementias affecting millions.
The team analyzed more than 3,000 cells from the brains of 28 patients who had either frontotemporal dementia or terminal-stage Alzheimer's. In the frontal cortex of Alzheimer's patients, a striking 35% of cells showed signs of karyoptosis—compared with just 15% in healthy older adults. This dramatic difference suggests the mechanism plays a significant role in the neuronal loss that drives memory decline and cognitive impairment.
What makes this finding particularly promising is that karyoptosis operates through a pathway that researchers believe can be interrupted. The team identified a critical interaction between a protein called p38 MAP kinase and another protein, LaminB1, that appears to act as a master switch controlling the nuclear disintegration characteristic of karyoptosis. When the researchers targeted this interaction in rat neurons in the lab, they were able to reduce markers of the cell death process.
"By specifically targeting the interaction between p38 MAP kinase and LaminB1, we may slow down the process of cell death, buying time for more pinpointed therapies against specific neurodegenerative diseases," said Dr. Manolis Fanto, a reader of functional genomics at King's College London.
The implications extend beyond the lab bench. For decades, scientists have known that toxic proteins accumulate in Alzheimer's and frontotemporal dementia but have struggled to understand exactly how this buildup leads to cell death. Karyoptosis now offers a concrete target. Dr. Rebecca Casterton, a senior researcher at the UK Dementia Research Institute and first author of the study, described it as laying out a roadmap for how this form of cell death operates—and a path forward for the field.
"The death and loss of cells in the brain drives many symptoms experienced by people living with dementia," Casterton said. "Our study uncovers a new series of chemical events that can coordinate cell death in brain cells. We have started to lay out the roadmap of how karyoptosis works, and I'm excited to see future breakthroughs this may drive in the dementia research community and beyond."
Alzheimer's Research UK, which helped fund the work, emphasized the significance for treatment development. "The identification of karyoptosis is a crucial step toward finding targets for treatments that could stop or slow cell loss," said Dr. Sara Rodrigues, the organization's senior research manager. "It could help widen the window for therapies that tackle the underlying causes of disease, bringing us closer to a cure for dementia."
Next, the team plans to explore precisely how to target the p38 MAP kinase and LaminB1 interaction in humans—work that could eventually open new avenues for drugs that slow or halt the cellular destruction at the heart of these diseases.